Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost

This article was originally published in The Pink Sheet Daily

Executive Summary

Tentative agreement closely resembles FDA's original proposal.

You may also be interested in...



Biosimilar User Fee Negotiations Won't Start Until 2016

Mid-December kick-off meeting puts emerging user fee program on much later track than others.

Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions

Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.

How Do You Solve A Problem Like Sequestration?

FDA and advocates wait for OMB to clarify how the estimated 7.8% budget cut should be implemented, if it is enacted. Former agency officials say it could lead to hiring freezes and program delays.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel